16Jun
Diligence Clauses and the Management of Uncertainty in Life Sciences Agreements
In times of uncertainty and disruption, setting expectations for performance with business partners and contractual counterparties can be more complicated than ever. Companies that develop drugs, biologics and medical devices have considerable...
By:
Skadden, Arps, Slate, Meagher & Flom LLP
Related
The United States-Mexico-Canada Trade Agreement (USMCA) is noteworthy for its novel “facility speci...
Read More >
A new amendment to the New York State Human Rights Law expressly prohibits workplace discrimination ...
Read More >
In response to the coronavirus (COVID-19) global pandemic, seven counties in California—Alameda, Co...
Read More >
The Federal Trade Commission, with the support of the Antitrust Division of the U.S. Department of J...
Read More >
On 17 March 2020, the UAE Cabinet issued the complete Positive List for FDI in the UAE, enumerating ...
Read More >
The Coronavirus (COVID-19) pandemic is bringing unprecedented disruption to the private M&A market. ...
Read More >